Domvanalimab

Summary

Domvanalimab (CHEMBL4650392) is a phase-3 clinical-stage antibody targeting TIGIT; indicated across 10 conditions including non-small cell lung carcinoma and adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (TIGIT)
• Indications: 10 conditions
• Clinical trials: 23

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650392
Name	Domvanalimab
Type	Antibody
Max phase	3

Also known as: AB-154, Ab154, AB154, Domvanalimab, DOMVANALIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TIGIT	TIGIT	Binding		0.1%	Q495A1

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TIGIT.

Dominant GO biological processes

GO term	Targets
negative regulation of interleukin-12 production	1
positive regulation of interleukin-10 production	1
negative regulation of natural killer cell mediated cytotoxicity	1
negative regulation of T cell activation	1
natural killer cell mediated cytotoxicity	1

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
adenocarcinoma	3	MONDO:0004970	EFO:0000228
neoplasm	2	MONDO:0005070	EFO:0000616
melanoma	2	MONDO:0005105	EFO:0000756
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
glioblastoma	0	MONDO:0018177	EFO:0000519

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 23.

Phase distribution

Phase	Trials
PHASE2	16
PHASE3	3
PHASE1	2
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05211895	PHASE3	RECRUITING	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05502237	PHASE3	ACTIVE_NOT_RECRUITING	Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05568095	PHASE3	ACTIVE_NOT_RECRUITING	A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT03547973	PHASE2	RECRUITING	Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT04736173	PHASE2	ACTIVE_NOT_RECRUITING	Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04791839	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
NCT05130177	PHASE2	ACTIVE_NOT_RECRUITING	Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
NCT05329766	PHASE2	ACTIVE_NOT_RECRUITING	A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05633667	PHASE2	RECRUITING	Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05676931	PHASE2	ACTIVE_NOT_RECRUITING	Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05724563	PHASE2	ACTIVE_NOT_RECRUITING	Domvanalimab and Zimberelimab in Advanced Liver Cancers
NCT06133517	PHASE2	ACTIVE_NOT_RECRUITING	PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer
NCT06250036	PHASE2	RECRUITING	Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
NCT06727565	PHASE2	ACTIVE_NOT_RECRUITING	Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06790706	PHASE2	RECRUITING	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
NCT07337447	PHASE2	NOT_YET_RECRUITING	Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)
NCT04262856	PHASE2	COMPLETED	Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT05419479	PHASE1/PHASE2	SUSPENDED	Switch Maintenance in Pancreatic
NCT07134556	PHASE2	WITHDRAWN	Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC
NCT07283848	PHASE2	WITHDRAWN	Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
NCT04999761	PHASE1	RECRUITING	AB122 Platform Study
NCT03628677	PHASE1	COMPLETED	A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
NCT04656535	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	AB154 Combined With AB122 for Recurrent Glioblastoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).